{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for etoposide root_names_stdName in Standardized Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
ANDA065488
(1991)
Source URL:
First approved in 1989
Source:
21 CFR 343
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT04026438: Phase 4 Interventional Completed Complication, Postoperative
(2019)
Source URL:
First approved in 1983
Source:
NADA125961
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Class:
MIXTURE
Status:
US Approved Rx
(2023)
Source:
BLA761204
(2023)
Source URL:
First approved in 2023
Source:
BLA761204
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:zeleciment basivarsen [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:delpacibart braxlosiran [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:delpacibart etedesiran [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT03319628: Phase 1/Phase 2 Interventional Active, not recruiting Platinum Resistant Ovarian Cancer
(2017)
Source URL:
Class:
PROTEIN
